4D Molecular Therapeutics (FDMT) EBIT (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported EBIT of -$73.6 million for Q1 2026, down 37.3% year-over-year from -$117.4 million in Q1 2025, and down 600.31% quarter-over-quarter from $14.7 million in Q4 2025.
4D Molecular Therapeutics (FDMT) EBIT (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of EBIT data on file, last reported at -$73.6 million in Q1 2026.
- EBIT for Q1 2026 came in at -$73.6 million, down 37.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$179.5 million (up 11.7% YoY), and the FY2025 annual result was -$159.5 million, up 15.06% from the prior year.
- EBIT retreated to -$73.6 million in Q1 2026 per FDMT's latest filing, from $14.7 million in the prior quarter.
- Over five years, EBIT peaked at $14.7 million in Q4 2025 and troughed at -$73.6 million in Q1 2026.
- A 5-year average of -$37.9 million and a median of -$36.7 million in 2023 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2025: EBIT sank 274.22% in 2022, then surged 126.22% in 2025.
- A 5-year view of EBIT shows it stood at -$28.7 million in 2022, then dropped by 27.62% to -$36.7 million in 2023, then slumped by 53.11% to -$56.1 million in 2024, then surged by 126.22% to $14.7 million in 2025, then tumbled by 600.31% to -$73.6 million in 2026.
- Business Quant data shows FDMT's EBIT at -$73.6 million in Q1 2026, $14.7 million in Q4 2025, and -$61.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -73.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.62 Mn |
| Dec 31, 2025 | 14.72 Mn |
| Sep 30, 2025 | -61.19 Mn |
| Jun 30, 2025 | -59.46 Mn |
| Mar 31, 2025 | -53.62 Mn |
| Dec 31, 2024 | -56.12 Mn |
| Sep 30, 2024 | -51.13 Mn |
| Jun 30, 2024 | -42.46 Mn |
| Mar 31, 2024 | -38.14 Mn |
| Dec 31, 2023 | -36.65 Mn |
| Sep 30, 2023 | -13.97 Mn |
| Jun 30, 2023 | -32.14 Mn |
| Mar 31, 2023 | -30.11 Mn |
| Dec 31, 2022 | -28.72 Mn |
| Sep 30, 2022 | -26.50 Mn |
| Jun 30, 2022 | -28.43 Mn |
| Mar 31, 2022 | -26.39 Mn |
| Dec 31, 2021 | -24.76 Mn |
| Sep 30, 2021 | -22.66 Mn |
| Jun 30, 2021 | -7.60 Mn |